Biosimilar User Fee Talks Begin With Industry Negotiating Amongst Itself
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA asks negotiators from the four industry groups to coordinate proposed changes as BsUFA renewal talks get underway.